Coming at 3 P.m.: I Talk Live to Jim Haslam, Who Has Investigated Covid's Origins for Years, About Ralph Baric, Tony Fauci, and the Rocky Mountain National Lab

Key Takeaways

• Live interview examines controversial COVID‑origin theories
• Jim Haslam presents new evidence linking Baric to lab work
• Baric’s research criticized for limited peer scrutiny
• Fauci’s role in funding discussed amid accountability calls
• Rocky Mountain lab highlighted as potential research hub

Summary

Alex Berenson announces a live interview at 3 p.m. ET with Jim Haslam, a longtime investigator of COVID‑19 origins. Haslam will discuss his new theory involving virologist Ralph Baric, Dr. Anthony Fauci, and the Rocky Mountain National Laboratory. The session follows Berenson’s recent exposé on Baric’s alleged evasiveness and research practices. Listeners are invited to join the webcast and evaluate the claims in real time.

Pulse Analysis

The upcoming webcast brings together Alex Berenson’s investigative reporting and Jim Haslam’s deep‑dive into the murky origins of SARS‑CoV‑2. Haslam, known for combing through FOIA requests and scientific publications, claims to have uncovered documentation that ties Ralph Baric’s coronavirus work to federal funding streams. By broadcasting the discussion live, the interview aims to democratize access to complex scientific debates that have traditionally been confined to academic circles, allowing investors, policymakers, and the public to assess the credibility of the evidence in real time.

Ralph Baric, a prominent coronavirus researcher at the University of North Carolina, has been a focal point of controversy since the pandemic began. Critics argue that his work on mouse‑adapted viruses and gain‑of‑function experiments lacked sufficient oversight, while supporters point to his contributions to vaccine development. The interview will probe Baric’s alleged ability to “avoid scrutiny,” a phrase that has surfaced in multiple media reports and congressional hearings. By contextualizing Baric’s research within the broader NIH funding framework and Dr. Anthony Fauci’s public health leadership, the conversation seeks to clarify whether scientific ambition crossed ethical boundaries.

The Rocky Mountain National Laboratory, mentioned briefly in Haslam’s theory, represents a lesser‑known node in the United States’ virology infrastructure. Its strategic location and partnership with federal agencies make it a potential site for high‑containment studies. Understanding its role could illuminate gaps in biosafety protocols and inform future legislative reforms. For business leaders monitoring biotech risk, the interview offers actionable insights into how research transparency—or the lack thereof—affects market confidence, regulatory landscapes, and public trust in scientific institutions.